Efficacy and Safety of Meloxicam (Mobicox®) in Mexican Population With Rheumatic Diseases

Study to evaluate the efficacy and safety of meloxicam (Mobicox®) in Mexican population with rheumatic diseases.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Osteoarthritis Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases

Age range

12 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

none

Exclusion criteria

Hypersensitivity to meloxicam or to other NSAIDS
History of asthma, angioedema or urticaria secondary to NSAIDS
Pregnancy or lactation
Recent or current history of peptic ulcer disease, severe renal failure, severe hepatic failure
Age below of 12 years.

Treatment and study plan

Primary outcomes

Change in intensity of the symptoms measured with a four-point scale

Time frame: Baseline, 30 and 90 days

Secondary outcomes

Degree of satisfaction evaluated with a six point numerical rating scale

Time frame: up to 90 days
Number of patients with adverse events

Time frame: up to 90 days

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

Clinical Therapeutic Evaluation Program in Patients With Rheumatic Diseases

Important dates

Study start: 2003
Primary completion: 2004
First posted: Jul 9, 2014
Registry last updated: Jul 9, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed